Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Opioid Dependence
Interventions
DRUG

Probuphine

4 implants

DRUG

placebo

4 implants

Trial Locations (18)

10010

New York VA Medical Center, NYU School of Medicine, New York

10019

Addiction Institute of New York, New York

19104

University of Pennsylvania Treatment Research Center, Philadelphia

21224

Behavioral Biology Research Unit, Johns Hopkins Bayview Campus, Baltimore

27705

Duke University Medical Center Addictions Program, Durham

30076

Northwest Behavioral Research Center, Roswell

32256

Amit Vijapura, MD and Associates, Jacksonville

33161

Scientific Clinical Research, Inc, North Miami

33319

Fidelity Clinical Research, Lauderhill

48207

Wayne State University Department of Psychiatry and Behavioral Neurosciences, Detroit

63128

Psych Care Consultants Research, St Louis

73118

Pahl Pharmaceutical Research, LLC, Oklahoma City

90025

David Geffen School of Medicine at UCLA, Los Angeles

91950

Synergy Clinical Research Center, National City

92056

North County Clinical Research, Oceanside

98108

Puget Sound Health Care Systems, Seattle

98206

Providence Behavioral Health Services, Everett

02720-6009

Dual Diagnosis Unit, SSTAR: Stanley Street Treatment and Resources, Inc., Fall River

Sponsors
All Listed Sponsors
lead

Titan Pharmaceuticals

INDUSTRY

NCT00447564 - Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence | Biotech Hunter | Biotech Hunter